论文部分内容阅读
目的:探讨自动乳腺全容积扫查系统(ABVS)对不同分子亚型乳腺癌新辅助化疗(NACT)疗效的评估价值。方法:以免疫组织化学技术为基础，根据雌激素受体(ER)、孕激素受体(PR)和原癌基因人类表皮生长因子受体2(HER2)阴性或阳性结果将乳腺癌分为3个分子亚型，即Luminal型(ER阳性或PR阳性，HER2阴性或阳性)、三阴型(ER、PR、HER2均阴性)和HER2过表达型(ER阴性、PR阴性、HER2阳性)。使用ABVS对比分析3种亚型共78例乳腺癌患者NACT期间肿瘤大小相关参数的变化情况及与病理结果的符合度。结果:与NACT前相比，Luminal型、三阴型和HER2过表达型在NACT后原发肿瘤的长、宽、高、面积及体积均有缩小(n P<0.05)，实体瘤疗效评价标准(RECIST)评价原发灶肿瘤完全缓解19例，部分缓解40例，ABVS观察总有效率与病理检测结果相符。各型肿瘤相关参数的变化与NACT次数呈线性相关(n P<0.05)，其中HER2过表达型拟合最好，在化疗第二个周期结束后原发灶肿瘤缩小明显，Luminal型与三阴型在化疗第三个周期结束后原发灶肿瘤缩小明显。n 结论:ABVS对不同分子亚型乳腺癌新辅助化疗疗效具有较好的评估价值。“,”Objective:To explore the value of Automated Breast Volume Scanner (ABVS) in evaluating the response of neoadjuvant chemotherapy(NACT) for different molecular subtypes of breast cancer.Methods:Based on immunohistochemical technique, breast cancer was divided into three molecular subtypes according to the negative or positive results of estrogen receptor (ER), progesterone receptor (PR) and proto oncogene human epidermal growth factor receptor 2 (HER2), namely luminal group [ER(+ ) or PR(+ ), and HER2(-/+ )], triple-negative group [ER(-), PR(-) and HER2(-)], HER2 group [ER(-), PR(-)and HER2(+ )]. ABVS was used to analyze the changes of tumor size related parameters in 78 breast cancer patients with three subtypes during NACT.Results:After NACT, the size , area and volume of primary lesion diminished obviously (n P<0.05). 19 cases achieved complete response and 40 cases achieved partial response according to response evaluation criteria in solid tumors (RECIST). After the end of the second cycle of NACT, the primary tumor shrank significantly in HER2 group, and luminal and tri-negative groups were significantly reduced after the end of the third cycle.n Conclusions:ABVS has a good value in evaluating the efficacy for different molecular substypes of NACT in breast cancer.